Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$69.77 USD

69.77
424,940

-1.44 (-2.02%)

Updated Oct 3, 2024 01:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (178 out of 252)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AmerisourceBergen's (ABC) Venture Capital Fund to Aid Healthcare

by Zacks Equity Research

AmerisourceBergen's (ABC) new corporate venture capital fund to help emerging healthcare startup companies change healthcare for people and animals globally.

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Henry Schein (HSIC) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to favorable dental business trends and a strong solvency position.

AmerisourceBergen (ABC) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about AmerisourceBergen's (ABC) strength in its World Courier business.

Here's Why You Should Invest In Henry Schein (HSIC) Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC) owing to the favorable dental business trends.

PerkinElmer (PKI) Boosts In Vivo Imaging Profile With New System

by Zacks Equity Research

PerkinElmer's (PKI) launch of the Vega imaging system is likely to help the company expand its in vivo imaging portfolio.

PerkinElmer's (PKI) New Assay Kits to Detect CHO HCP Impurities

by Zacks Equity Research

PerkinElmer (PKI) launches ready-to-use HTRF and AlphaLISA no-wash assay kits to quickly identify and quantify CHO HCP impurities.

Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint

by Zacks Equity Research

Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.

Baxter's (BAX) ST Set Receives FDA Nod, to Boost Patient Outcome

by Zacks Equity Research

Baxter's (BAX) ST Set is expected to improve treatments in an acute care environment.

Here's Why You Should Retain Cooper Companies (COO) Stock Now

by Zacks Equity Research

Cooper Companies (COO) continues to benefit from strength in its business segments.

Here's Why You Should Retain Merit Medical (MMSI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.

Shockwave Medical's (SWAV) New Launch to Lower IVL Treatment Time

by Zacks Equity Research

Shockwave Medical's (SWAV) latest global commercial launch is expected to serve a more diverse patient pool.

DexCom's (DXCM) Upcoming Launch to Boost Diabetes Management

by Zacks Equity Research

DexCom's (DXCM) upcoming launch of Dexcom ONE CGM can help people in the U.K. to manage diabetes.

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

Accuray's (ARAY) CyberKnife Effective for Relief From TN Pain

by Zacks Equity Research

Latest data indicates that Accuray's (ARAY) CyberKnife System is effective in providing long-lasting pain relief to patients suffering from TN.

Zimmer Biomet (ZBH) Hurt by China VBP, COVID-Led Staff Shortage

by Zacks Equity Research

Zimmer Biomet (ZBH) expects to face an adverse pricing impact in the first half of 2022, which is being compared to the non-VBP first half of 2021.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

NextGen (NXGN) Introduces New Integrated Care EHR Solution

by Zacks Equity Research

NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.

Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty

by Zacks Equity Research

Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.

3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.

Why Henry Schein (HSIC) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here's Why You Should Retain Universal Health (UHS) Stock Now

by Zacks Equity Research

Increased admissions at both of its operating segments, constant initiatives to bolster its care network and adequate cash generation abilities are likely to drive Universal Health (UHS).

Cardinal Health (CAH) to Extend Medical Distribution Presence

by Zacks Equity Research

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.